Commentary: Indocyanine green: The Green Lantern of congenital heart surgery?

Emani, Sitaram M.

doi:10.1016/j.xjtc.2021.05.018

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indocyanine green (ICG) is an FDA-approved contrast agent widely used in imaging various organs, especially the heart. − Based on its unique photochemical and photobiological properties, indocyanine green has been developed by researchers as a fluorescent contrast medium and a photosensitizer for photothermal therapy , (Figure a). To improve the therapeutic efficacy of ICG, many studies have sought to enhance the permeability of ICG in specific tissues, especially in tumors. , Related studies have combined ICG with nanomaterials such as proteins, liposomes, and micelles to create nanoparticles capable of achieving multiple functions. , Recent studies have shown that ICG can form self-assembled nanoparticles due to its unique structure, and it has been found that this spontaneous assembly is hydrogen-bond-driven.…”

Section: The Driving Forces In Supramolecular Self-assemblymentioning

confidence: 99%

Review of Carrier-Free Self-Assembly of Anticancer Nanodrugs

Ji,

Wang,

Qiao

et al. 2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Nanodrugs represent a drug delivery form that brings hope for optimal drug release due to their inherent properties. Special carrier materials give hydrophobic drugs excellent water solubility, and coupled with their small size and delicate design, the uptake of drugs by specific tissues can be enhanced. However, problems such as the rejection of exogenous carriers and the toxicity of the carriers themselves have prevented the clinical translation of nanodrugs. In recent years, the emergence of carrier-free nanodrugs has led to promising results to solve the above problems. In recent years, supramolecular self-assembled nanodrugs formed by non-covalent bonds have been a hot research topic. This review systematically evaluates currently available information on the dynamics of supramolecular self-assembled nanodrug formation and presents the advances in single-component, two-component, and multicomponent self-assembled nanoparticles in tumor therapy. Then it explores how these carrier-free nanodrugs could be functionally optimized based on the perspective of marketed drugs. Last but not least, it analyzes the marketed drugs with supramolecular self-assembly potential. Importantly, these findings could be instrumental in refining the drug delivery systems of novel drugs.

show abstract